Puretech Health‘s patent involves genetically engineered hematopoietic cells with edited genes for treating hematopoietic malignancies like acute myeloid leukemia. The method includes administering cells with reduced CD33 and CD123 expression along with agents targeting these proteins. GlobalData’s report on Puretech Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Puretech Health Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Puretech Health, Peptide pharmacophores was a key innovation area identified from patents. Puretech Health's grant share as of February 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of acute myeloid leukemia using genetically engineered cells

Source: United States Patent and Trademark Office (USPTO). Credit: Puretech Health Plc

A recently granted patent (Publication Number: US11903973B2) outlines a method for treating hematopoietic malignancies, specifically acute myeloid leukemia (AML). The method involves administering genetically engineered hematopoietic cells (HCs) to a subject, where the cells are modified to have reduced or eliminated expression of CD33 and CD123 genes. Additionally, a therapeutically effective amount of an agent with anti-CD33 or anti-CD123 binding domains is also administered to the subject.

Furthermore, the patent details the process of preparing a population of genetically engineered HCs by modifying cells obtained from a human subject to reduce or eliminate the expression of CD33 and CD123 genes. The genetically engineered HCs are capable of normal differentiation, expansion, and engraftment, making them a potential treatment option for hematopoietic malignancies. The method involves precise genetic modifications using a CRISPR system and specific guide nucleic acid sequences to achieve the desired reduction in gene expression levels, ultimately offering a promising approach for treating AML and other hematopoietic malignancies.

To know more about GlobalData’s detailed insights on Puretech Health, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies